title: A complication-free course ensures a survival advantage in patients after regional therapy for metastatic colorectal cancer.
abstract: Hepatic artery infusional (HAI) chemotherapy has been shown to favorably impact outcome in patients with metastatic colorectal cancer, but complications often preclude complete treatment. The purpose of this study was to determine whether HAI complications impact survival in these patients. Patients undergoing HAI pump placement at our institution from September 2001 to July 2004 were separated into terciles based on the number of treatments completed: < or = 1 (none), 2 to 4 (partial), and > or = 5 (complete). Complications relating to pump placement or treatment were recorded for each and their impact on survival was determined. Kaplan-Meier survival in 15 patients receiving no treatment was significantly shorter than 7 patients completing therapy (P = 0.02). Thirty-three per cent of patients receiving no therapy were alive at 26 months, whereas 63 per cent of partially and 86 per cent of completely treated patients were alive at 32 and 30 months, respectively. Patients receiving no treatment had more overall complications (80%) and significantly (P < 0.05) more pump-related complications (60%) than those completing therapy (43% and 0%, respectively). Cox regression revealed a significant correlation to gender (hazard ratio, 3.9), tumor size (hazard ratio, 1.17), and carcinoembryonic antigen level (hazard ratio, 1.02) to survival. Patients receiving complete HAI treatment survive longer than those receiving no treatment. Potentially preventable pump-related complications not only impacted the patients' ability to continue therapy, but survival times as well.
authors.affiliation: Department of Surgery, Division of Digestive Diseases and Science, University of South Florida, Tampa, USA.
authors.forename: Dana
authors.initials: D
authors.lastname: Osborne
authors.forename: Effie
authors.initials: E
authors.lastname: Pappas
authors.forename: Gerald
authors.initials: G
authors.lastname: Alexander
authors.forename: Brian
authors.initials: B
authors.lastname: Boe
authors.forename: Alan B
authors.initials: AB
authors.lastname: Cantor
authors.forename: Alexander
authors.initials: A
authors.lastname: Rosemurgy
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Zervos
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D017115:Catheter Ablation; D015179:Colorectal Neoplasms / Q000473:pathology*; D003131:Combined Modality Therapy; D005260:Female; D006498:Hepatectomy; D006499:Hepatic Artery; D006801:Humans; D015918:Infusion Pumps, Implantable / Q000009:adverse effects; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms / Q000401:mortality* / Q000556:secondary / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents